Medicines Co buys antibiotic-maker Rempex
Dec 4 (Reuters) - Medicines Co on Wednesday said it acquired privately held Rempex Pharmaceuticals Inc, which develops medicines against drug-resistant bacteria, for $140 million and potential future milestone payments of up to $334 million.
Medicines Company said it acquires several anti-infective drugs as part of the deal, including a promising experimental medicine called Carbavance that has completed early-stage trials.
The company said it will continue to develop other experimental drugs from Rempex that also treat gram-negative bacteria in hospital settings.
- Gaza rockets land deep in Israel as it bombards Palestinian enclave |
- Anger mounts as Germany unearths second U.S. spy suspect
- Both candidates in Indonesia election claim victory; Jokowi ahead in more counts |
- Argentina, Netherlands set for battle, Brazil wonders what happened
- Former New Orleans Mayor Nagin gets 10 years in corruption case